Takeda

Takeda Pharmaceutical said Tuesday it has committed up to a staggering $6 billion—including $4 billion upfront—to acquire from Nimbus Therapeutics a candidate for multiple autoimmune diseases that is Phase III-bound in psoriasis after showing positive mid-stage results last month. NDI-034858 is an oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2), which Takeda will rename TAK-279…

Nimbus Therapeutics’ midphase psoriasis data have persuaded Takeda that the biotech’s TYK2 inhibitor will be big. How big? $4 billion upfront and more again on the back end. | Nimbus Therapeutics’ midphase psoriasis data have persuaded Takeda that the biotech’s TYK2 inhibitor will be big. How big? $4 billion upfront and more again on the…

The future of the pharma industry will be shaped by a range of disruptive themes, with artificial intelligence (AI) being one of the themes that will have a significant impact on clinical trials companies.  The pharma industry is a highly regulated industry, and therefore can be slow to adopt new technologies and modernise. However, the…

T akeda, headquartered in Japan, is a leading global biopharmaceutical company, one of the largest in Asia and among the top 15 globally by revenue. Takeda’s global CFO, Costa Saroukos, shaped the vision for finance in which employees “deliver insights and drive value for patients.” He described…

Shortly after announcing plans to transform itself into a digital, “cloud-first” drugmaker, Takeda has extended its agreements with Seqster—a company wh | Shortly after announcing plans to transform itself into a digital, “cloud-first” drugmaker, Takeda has extended its agreements with Seqster—a company whose founder describes it as the Mint.com of patient healthcare data.